David Mafigiri Kaawa
ID: UNCST-2019-R001276
|
Assessing the effectiveness of the 'Reaching Every Community using Quality Improvement methods' (REC-QI) approach in strengthening the Routine Immunization system in six districts in Uganda
REFNo: HS109ES
• To develop quantitative and qualitative measures to assess dimensions of the RI system that have been strengthened and where problems persist, identify the reasons for them.
• Describe adaptations to the implementation of REC-QI that enable districts to move along the continuum of “Orient†to “Establish and Strengthen†to “Sustain.â€
|
Uganda |
2017-08-28 |
2020-08-28 |
Medical and Health Sciences |
|
Non-degree Award |
|
David Mafigiri Kaawa
ID: UNCST-2019-R001276
|
LIVED EXPERIENCES, CHALLENGES AND OPPORTUNITIES OF DEMENTIA PATIENTS AND THEIR FAMILIES IN URBAN, KAMPALA
REFNo: SS1152ES
• To assess perceptions of dementia among family caregivers of patients.
• To assess the nature of the lived experiences of family caregivers of patients with dementia.
• To examine the challenges of dementia patients and their family caregivers.
• To identify workable opportunities for mitigating the challenges of dementia patients and caregivers.
|
Uganda |
2022-02-21 |
2025-02-21 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
David Mafigiri Kaawa
ID: UNCST-2019-R001276
|
Rapid Anthropological Study in Districts Affected by Ebola (Sudan Strain) in Uganda
REFNo: SS1542ES
The general objective of this study is to explore the socio-cultural construction of the drivers of the current Ebola virus disease (EBV) transmission and community resistance to Ebola response strategies in Uganda
|
Uganda |
2022-12-08 13:08:41 |
2025-12-08 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
David Mafigiri Kaawa
ID: UNCST-2019-R001276
|
Testing on the frontline: empowering health engagement through ‘rational use’ of diagnostics for infectious and non-communicable disease (TIYENI Dx)
REFNo: SS5125ES
1. To define ‘rational use’ from the perspective of users, families, communities and frontline health workers and document social and structural drivers of self-testing for self-care under specific external conditions of stigma, emergency disease outbreaks and lifestyle and risk management for chronic disease across mainstream and marginalised groups.
2. To unpack the dynamic between empowerment through self-testing and engagement with public and private health services including the role of frontline health providers influencing self-testing in different contexts and potential for linkage to health and data systems.
3. To explore discourses of uncertainty, trust and risk influencing individual, family, community and frontline health worker decisions, embedded within complex socio-ecological environments and the impact of these on intended and unintended, beneficial and potentially harmful health and social consequences of self-testing.
4. To co-production of toolkits for ‘rational use’ of frontline diagnostics including community review of the UNICEF ‘Lets Test Toolkit’ and co-adaptation of self-testing generic and self-testing specific implementation guidelines and instructions for use.
5. To promote health equity across mainstream and marginalised groups in access to and ‘rational use’ of self-testing and monitoring that appropriately reflects future direct to consumer markets through a) informing country level strategies on frontline diagnostics as part of national health plans and b) developing a theoretical framework for people-centred ‘rational use’.
|
Uganda |
2026-04-20 16:06:19 |
2029-04-20 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Charles Mondo Kiiza
ID: UNCST-2019-R001281
|
A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension
REFNo: HS113ES
Primary objective: To evaluate the antihypertensive effect of AZM compared with placebo after a randomized, double-blind, withdrawal (Withdrawal Phase).
Secondary objectives: To evaluate the antihypertensive effect of AZM compared with losartan during double-blind treatment (Double-Blind Phase).
Additional Objectives: To assess the population pharmacokinetics of azilsartan derived from AZM.
|
Uganda |
2017-11-20 |
2020-11-20 |
Medical and Health Sciences |
|
Non-degree Award |
|
Charles Mondo Kiiza
ID: UNCST-2019-R001281
|
Registry to study the demographics, socioeconomic and clinical factors, etiologies, pathophysiology, management, barriers to care, and outcomes of heart failure patients at St. Francis Hospital Nsambya.
REFNo: HS287ES
1. Estimate the incident rate of outcomes in HF patients in Uganda; assess social and lifestyle factors (incl. demographics, socioeconomic variables, clinical risk factors, diet, and health-related quality of life), etiologies and variations in treatment patterns that might influence mortality and morbidity.
2. Describe determinants of different HF phenotypes (HFpEF, HFrEF, and HF due to valvular heart disease and ALVD), and their management and outcomes.
3. Assess non-cardiac co-morbidities at enrolment, their incidence during the study, and how they influence outcomes from both cardiovascular and non-cardiovascular mortality and morbidity.
4. In a sub-study of approximately 50-60 patients, perform measures of frailty, cognitive and lung function, mental health, adherence to medication, and dietary assessment, with collection of blood and urine samples for central analysis, to further understand the pathophysiologic changes in HF and their relation to outcomes.
5. Describe patient and system barriers to HF care.
|
Uganda |
2019-07-30 |
2022-07-30 |
Medical and Health Sciences |
|
Non-degree Award |
|
Kavuma Mwanje Arthur
ID:
|
CORRELATION BETWEEN CD4 CELL COUNTS AND THE IMMUNE STATUS AMONG CRITICALLY ILL HIV NEGATIVE PATIENTS ADMITTED TO INTENSIVE CARE UNITS
REFNo: HS104ES
General objective
To assess the immune status of critically ill HIV negative patients admitted to Ugandan ICUs using CD4 T cell counts as a surrogate marker.
Specific objectives
Primary objectives
i. To determine the CD4 T cell counts among critically ill HIV negative patients admitted to Ugandan ICUs.
ii. To determine the relationship between CD4 T cell counts and a twenty eight day ICU mortality among the critically ill HIV negative patients admitted to the Ugandan ICUs.
Secondary objective
iii. To assess the feasibility of using CD4 T cell counts to predict 24 hour mortality or disease severity as compared to APACHE II score among the critically ill HIV negative patients admitted to Ugandan ICUs
|
Uganda |
2017-09-05 |
2020-09-05 |
Medical and Health Sciences |
|
Degree Award |
|
Niina Marja Ahola Marja
ID:
|
Life After Return – Revisiting the Reintegration of Former Lord’s Resistance Army Abductees in Acholiland Region of Northern Uganda
REFNo: SS130ES
The key objective of this study is to increase knowledge on the reintegration process in post-conflict situations in general and the reintegration of former Lord’s Resistance Army (LRA) abductees in particular.
This research gives voice to the former LRA abductees regarding their experiences of reintegration. The objective is to find out which factors have either promoted or prevented their process of integration back to society along the years, as it has been now a decade since the conflict in northern Uganda ended. Therefore, this study seeks to offer information on the challenges and successes that the former abductees have faced along their reintegration process, relying on their own experiences as the main source of data.
In addition, one of the objectives of this study is to gather data for the investigator’s Master’s thesis.
|
Finland |
2017-12-20 |
2020-12-20 |
Social Science and Humanities |
|
Degree Award |
|
Adrian Muwonge
ID:
|
The dynamics of antimicrobial resistance (AMR) genes in the pig and human gut microbiome in Uganda
REFNo: HS103ES
The hypothesis to be tested is that people in contact with pigs in peri-urban settings are at higher risk of acquiring AMR genes across this interface than people in rural settings.
The specific objectives are:
1. To identify significant changes in taxonomic and AMR genes in gut microbiomes of people and their pigs in peri urban and rural settings over a one-year period using 16SrRNA, AMR gene probes and real time PCR.
2. To conduct forensic investigations of the significant changes detected in objective 1 using sequence based metagenomics on the corresponding gut microbiomes in parallel with whole genome sequencing and phenotypic AMR testing of sentinel bacteria to understand the underlying dynamics.
3. To predict, estimate and make inferences on AMR gene occurrence, taxa-linked within and between host exchange and their potential phenotypic effects using bioinformatic, statistical and support vector machine approaches on the data generated in 1&2.
|
Uganda |
2017-10-11 |
2020-10-11 |
Medical and Health Sciences |
|
Non-degree Award |
|
Adrian Muwonge
ID:
|
Piloting a Digital One Health platform for AMR surveillance
REFNo: HS3391ES
1.Testing the utility of our mobile phone application prototype for harmonizing metadata capture
2. Piloting the use of long-read sequencing of routinely cultured pathogens (Escherichia coli and Klebsiella spp.)
3. Developing a portable and integrated data workflow to feed into our prototype data sharing and analysis web portal
4.Supporting local capacity building through training seminars on long read sequencing and data analysis.
The output of this project will allow us to demonstrate and evaluate the feasibility and challenges of integrating One Health as a shared resource
|
Uganda |
2023-12-19 11:27:37 |
2026-12-19 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Ronald Mayanja
ID:
|
Primary High Risk HPV Testing for Cervical Cancer Screening in a Community Health Fair Setting
REFNo: HS102ES
To pilot the implementation of high-risk self-testing in a community health fair setting with a mobile phone-based results notification to facilitate follow up treatment at a local health facility.
Aim 1: Determine the feasibility of implementing cervical cancer screening at community health fairs in rural Uganda using self-sampled hrHPV testing
Aim 2: Understand rural Ugandan women’s acceptability, barriers and facilitators of self-collected sampling for cervical cancer screening
Aim 3: Assess the ability of Web SMS to improve workforce efficiency and follow up of cervical cancer testing results in community settings.
|
Uganda |
2017-08-21 |
2020-08-21 |
Medical and Health Sciences |
|
Non-degree Award |
|
Ronald Mayanja
ID:
|
CERVICAL CANCER AND ITS PRECURSORS IN HIV INFECTED YOUNG (BELOW THIRTY YEARS OLD) WOMEN AT MBARARA REGIONAL REFERRAL HOSPITAL, UGANDA.
REFNo: HS178ES
General Study Objective
The main objective of this study is to determine the prevalence and factors associated with cervical cancer and its precursors among HIV infected young (below thirty years old) women at Mbarara Regional Referral Hospital.
Specific Objectives
1. To compare the prevalence, histological types, trends and factors associated with cervical cancer amongst HIV-positive and HIV-negative young (below thirty years old) women attending the colposcopy and cervical pathology clinic of Mbarara regional referral hospital.
2. To determine the prevalence of high grade cervical intraepithelial lesions and associated factors among HIV infected young (below thirty years old) women at Mbarara Regional Referral Hospital.
3. To determine the factors associated with cervical intraepithelial neoplasia tissue Immunological response among HIV infected young (below thirty years old) women attending the colposcopy and cervical pathology clinic of Mbarara regional referral hospital?
4. To determine the epidemiological and prognostic factors associated with cervical cancer precursors among HIV infected young (below thirty years old) women at Mbarara Regional Referral Hospital.
|
Uganda |
2018-08-07 |
2021-08-07 |
Medical and Health Sciences |
|
Degree Award |
|
Dave Darshit
ID:
|
THE ASSOCIATION BETWEEN NUTRITIONAL STATUS, ADHERENCE AND PHARMACOKINETICS OF ATAZANAVIR AMONG HIV POSITIVE ADOLESCENTS ATTENDING AN HIV OUTPATIENT CLINIC IN AN URBAN SETTING IN UGANDA.
REFNo: HS100ES
i. To determine the prevalence of malnutrition among HIV positive adolescents on ATV based on different growth parameters.
ii. To determine the association between nutritional status and adherence to ART among HIV positive adolescents on ATV based regimen.
iii. To describe the association between nutritional status and pharmacokinetics of boosted ATV among HIV positive adolescents.
|
India |
2017-09-12 |
2020-09-12 |
Medical and Health Sciences |
|
Non-degree Award |
|
Mohammed Lamorde
ID: UNCST-2019-R001293
|
Dolutegravir in Pregnant HIV Mothers and their Neonates DolPHIN-2
REFNo: HS106ES
To evaluate dolutegravir (DTG) efficacy in late-presenting pregnant HIV-infected women
|
Nigeria |
2017-12-20 |
2020-12-20 |
Medical and Health Sciences |
|
Non-degree Award |
|
Mohammed Lamorde
ID: UNCST-2019-R001293
|
A PHARMACOKINETIC EVALUATION OF ETONOGESTREL IMPLANT IN HIV-INFECTED WOMEN ON DARUNAVIR VERSUS RIPILVIRINE-BASED ANTIRETROVIRAL THERAPY (DRIVE-I)
REFNo: HS145ES
Primary objective:
To compare the PK of ENG (68 mg) contraceptive implant over 6 months in Ugandan HIV-infected women receiving DRV-based ART or RPV-based ART versus historical controls
Secondary objectives:
(1) To predict the disposition of ENG over the subsequent 2.5 years of intended use through PK modeling of ENG concentrations beyond 12 months of use in HIV-infected women using DRV- or RPV-based ART
(2) To describe the PK exposure over 12 months of ENG contraceptive implant in Ugandan HIV-infected women receiving DRV-based ART or RPV-based ART
(3) To describe the pharmacokinetics of DRV 12 hours post-dose (C12) and RPV 24 hours post-dose (C24) prior to and during 12 months of combined use with ENG.
(4) To describe the safety and tolerability of combined use of DRV/RTV or RPV and ENG during 12 months of combined use.
(5) To describe the relationship between ENG concentrations and participant specific covariates including body weight, albumin, sex-hormone binding globulin and pharmacogenetic factors.
|
Nigeria |
2018-01-29 |
2021-01-29 |
Medical and Health Sciences |
|
Non-degree Award |
|
Mohammed Lamorde
ID: UNCST-2019-R001293
|
A PHARMACOKINETIC EVALUATION OF LEVONORGESTREL IMPLANT IN HIV-INFECTED WOMEN ON DARUNAVIR VERSUS RIPILVIRINE-BASED ANTIRETROVIRAL THERAPY (DRIVE-II)
REFNo: HS146ES
Primary objective: To compare the PK of LNG (150 mg) contraceptive implant over 6 months in Ugandan HIV-infected women receiving DRV-based ART or RPV-based ART versus historical controls.
Secondary objectives:
(1) To compare the PK of LNG over 12 months among women receiving DRV-based ART or RPV-based ART versus historical controls
(2) To predict the disposition of LNG over the subsequent 4 years of intended use through PK modeling of LNG concentrations beyond 12 months of use in HIV-infected women using DRV- or RPV-based ART
(3) To describe the pharmacokinetics of DRV 12 hours post-dose (C12) and RPV 24 hours post-dose (C24) prior to and during 12 months of combined use with LNG.
(4) To describe the safety and tolerability of combined use of DRV/r or RPV and LNG during 12 months of combined use.
(5) To describe the relationship between LNG concentrations and participant specific covariates including body weight, albumin, sex-hormone binding globulin and pharmacogenetic factors.
|
Nigeria |
2018-01-29 |
2021-01-29 |
Medical and Health Sciences |
|
Non-degree Award |
|
Mohammed Lamorde
ID: UNCST-2019-R001293
|
Steady-state pharmacokinetics of efavirenz (Sustiva/Stocrin) 400 mg once daily in the presence of rifampicin and isoniazid (Rifinah or the local generics)
REFNo: HS161ES
Primary Objective: To evaluate the steady-state pharmacokinetics of efavirenz (Sustiva/Stocrin) 400 mg once daily during co-administration with rifampicin and isoniazid (Rifinah or local generic)
Secondary Objectives:
1. To assess the safety and tolerability of efavirenz (Sustiva/Stocrin) 400 mg once daily during co-administration with rifampicin and isoniazid (Rifinah or local generic)
2. To investigate the association between genetic polymorphisms in drug disposition genes and drug exposure.
|
Nigeria |
2018-02-06 |
2021-02-06 |
Medical and Health Sciences |
|
Non-degree Award |
|
Mohammed Lamorde
ID: UNCST-2019-R001293
|
Pharmacokinetic and pharmacodynamic evaluation of etonogestrel dose escalation with efavirenz-based antiretroviral therapy in HIV-infected Ugandan women (DoublET)
REFNo: HS163ES
Primary objective:
To compare the rate of ovulation (by weekly endogenous progesterone at months 3, 6, and 12) when women receive two 68 mg ENG implants (dose-escalated) compared to one 68 mg ENG implant (standard dose) in combination with EFV-based ART.
Secondary objectives:
1. To determine cervical mucus quality (by collecting weekly WHO cervical mucus scores at months 3, 6, and 12) when women receive two 68 mg ENG implants (dose-escalated) compared to one 68 mg ENG implant (standard dose) in combination with EFV-based ART.
2. To compare the PK parameters of two ENG implants (136 mg total) with combined EFV use versus the standard dose 68 mg ENG implant with no ART (historical controls in the same population using the same laboratory1) over 6 months of combined use.
3. To evaluate the safety and tolerability of two ENG implants with combined EFV-based ART use.
4. To describe the relationship between ENG concentrations and participant specific variables, specifically body weight, albumin, sex hormone binding globulin, pharmacogenetic polymorphisms, and ART concentrations.
5. To describe the long term feasibility and tolerability of increased dose ENG (136mg) subdermal implant use in HIV-infected women receiving EFV-based ART after weeks 96 and 144 of combined use.
|
Nigeria |
2018-02-21 |
2021-02-21 |
Medical and Health Sciences |
|
Non-degree Award |
|
Mohammed Lamorde
ID: UNCST-2019-R001293
|
Clinical Evaluation of the FilmArray Global Fever (GF) Panel
REFNo: HS265ES
To evaluate the clinical sensitivity and specificity of the assays comprising the FilmArray GF Panel when used to test whole blood specimens. It is hypothesized that the FilmArray GF Panel assays will detect clinically relevant levels of the pathogens included in the panel and give no false detections.
|
Nigeria |
2018-12-04 |
2021-12-04 |
Medical and Health Sciences |
|
Non-degree Award |
|
Mohammed Lamorde
ID: UNCST-2019-R001293
|
Current and prior viral zoonotic infections among adults admitted with acute febrile illness in North and Central Uganda
REFNo: HS371ES
Primary objective:
To determine the prevalence of 1) current and 2) prior viral zoonotic infections among hospitalized adults with acute febrile illness in Northern and Central Uganda
Secondary objectives:
1.To determine epidemiologic or historical risk factors associated with a) viral zoonotic infections and b) resistant bacterial infections.
2.To determine the prevalence of bacteremia and antibacterial resistance among hospitalized adults with acute febrile illness.To characterize clinical factors associated with antibiotic prescription and discontinuation among patients hospitalized with acute febrile illness.
|
Nigeria |
2019-07-01 |
2022-07-01 |
Medical and Health Sciences |
|
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|